Beam Therapeutics Inc's Suppliers recorded an increase in sales by 17.37 % year on year in Q2 2026, sequentially sales grew by 16.69 %, while their net margin rose to 16.12 % year on year, Beam Therapeutics Inc's Suppliers improved sequentially profit margin to 16.69 %,
Beam Therapeutics Inc's Suppliers recorded an increase in sales by 17.37 % year on year in Q2 2026, sequentially sales grew by 16.69 %, while their net margin rose to 16.12 % year on year, Beam Therapeutics Inc's Suppliers improved sequentially profit margin to 16.12 %,
The company sources raw materials from biological sources, which can be challenging to procure and may be subject to contamination or recall, potentially affecting manufacturing and development timelines. It relies on third parties, including contract manufacturing organizations (CMOs), contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to manufacture product components, conduct clinical trials, and perform research and preclinical testing. These third parties may terminate their engagements, potentially causing delays. The company remains responsible for compliance with regulatory standards such as Good Clinical Practices and clinical trial registration requirements. Reliance on CROs results in many aspects of development programs being outside the company's direct control.
Beam Therapeutics Inc's Comment on Supply Chain
The company sources raw materials from biological sources, which can be challenging to procure and may be subject to contamination or recall, potentially affecting manufacturing and development timelines. It relies on third parties, including contract manufacturing organizations (CMOs), contract research organizations (CROs), clinical data management organizations, medical institutions, and clinical investigators, to manufacture product components, conduct clinical trials, and perform research and preclinical testing. These third parties may terminate their engagements, potentially causing delays. The company remains responsible for compliance with regulatory standards such as Good Clinical Practices and clinical trial registration requirements. Reliance on CROs results in many aspects of development programs being outside the company's direct control.
BEAM's Suppliers Net Income grew by
BEAM's Suppliers Net margin grew in Q2 to
126.2 %
16.12 %
BEAM's Suppliers Net Income grew by 126.2 %
BEAM's Suppliers Net margin grew in Q2 to 16.12 %
Beam Therapeutics Inc's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Beam Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Beam Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
9.63 % 